JERUSALEM, September 24, 2015 /PRNewswire/ —
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (https://www.oramed.com), a developer of oral drug delivery systems, announced today that the Company’s patent for its invention, titled “Methods and Compositions for Oral Administrations of Proteins” has been allowed by the United States Patent and Trademark Office.
Nadav Kidron, CEO of Oramed, stated, “This is an important milestone which paves our entrance into the US diabetes market which is the largest single diabetes market worldwide.”
About ORMD-0801 Capsule for Type 2 Diabetes
ORMD-0801 has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment, potentially slowing disease progression and delaying or even eliminating late-stage complications. Orally administered insulin should bring with it enhanced patient compliance. In addition, intestinally absorbed-oral insulin actually mimics insulin’s natural location and gradients in the body by first passing through the liver before entering the bloodstream.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed’s Protein Oral Delivery (POD